Development

Editor of Pharmaceutical Technology Europe

Articles

The inhaled route of administration for biologics is experiencing renewed interest, particularly in light of the COVID-19 pandemic.

Taking a Breath: Advances in Inhaled Biologics

The European Commission has approved Lynparza (olaparib) for use in patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer within the European Union.

European Commission Approves Lynparza for BRCA-Mutated Metastatic Pancreatic Cancer

Kindeva Drug Delivery plans capital investment and jobs growth.

Former 3M Drug Delivery Systems Launches as Kindeva Drug Delivery

The technology uses a silica nanoparticle to deliver vaccines and cancer treatments.

N4 Pharma Develops Nanoparticle Technology for Vaccine Delivery

The drug particle engineering and nanotechnology company offers a nanotechnology platform that can revive failed drugs in the pharma pipeline.

Nanoform Invests in Nanoparticle Technology for Drug Development

The authors of the study believe it could have significant implications for the discovery of new dermatological products for major diseases such as psoriasis.

New Study Challenges Current Theories on Skin Delivery of Macromolecules

Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology. 

Japanese Agency Supports Daiichi Sankyo’s Genetic Vaccine Platform

Gelest, a manufacturer and provider of silane, silicone, and metal-organic compounds, released a range of dual-function poly(ethylene glycol) (PEG) reagents that enable new approaches to PEGylation for bioconjugates. 

PEGylation Reagents for Drug Delivery

Adeline Siew is science editor for BioPharm International.

There is a lot of interest in delivering biologics via non-invasive routes in attempt to improve patient compliance and convenience. 


Formulation of Biologics for Non-Invasive Delivery

The United Kingdom’s Center for Process Innovation (CPI) is investing in a new project, Microstar, which seeks to reduce risk for formulators through the development of accelerated screening methods for predictive design.

Formulation and Drug Delivery, Other